NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025
This is a contract result notice, not an open opportunity. Details from the official award data.
The procurement contact named on the official notice.
NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025<br/>CM/PHR/24/5680/01 - Tranche B for North of England and Midlands & East.
Period of Framework Agreement: 01 September 2025 to 31 August 2027 <br/>CM/PHR/24/5680/02 - Eculizumab and Ravulizumab for London & SOFE.
Period of Framework Agreement: 01 September 2025 to 31 August 2026
What this notice demands of you
1 named, none in explicit obligation language. Each one is quoted from the notice.
NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025
Matched against the notice text, so this is a floor — the tender pack will demand things the notice never mentions. “Says must” means the quoted sentence itself used obligation language; anything ambiguous is left as a mention.
Make the case to bid
Reveal who to approach at NHS England, and generate a go-to-market strategy from their news, accounts and people.
Free to start. Named contacts come from published notices; the strategy is generated from the buyer’s news, accounts and people.
- OCID
- ocds-h6vhtk-04e273
- Stage
- award · Awarded
- Source
- Find a Tender
- Buyer ref
- 043951-2025
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
Top suppliers & buyers in Medical Equipment & Pharmaceuticals
NHS England’s tender network